ArticleCureus2025
Lymphoepithelioma-Like Carcinoma of the Urinary Bladder: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparative analysis of clinicopathological characteristics and prognosis between E-cadherin-negative breast lymphoepithelioma-like carcinoma and E-cadherin-negative invasive lobular carcinoma.World journal of surgical oncology · 2026Article
- Lymphoepithelioma-like carcinoma of the bladder: a case report.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphoepithelioma-like carcinoma (LELC) of the bladder is a rare variant of urothelial carcinoma that histologically resembles lymphoepithelioma of the nasopharynx. Due to its rarity, prognostic outcomes and optimal treatment strategies remain unclear. We present the case of a 60-year-old male who presented with gross hematuria. Imaging revealed an anterior bladder wall mass. The patient underwent transurethral resection of a papillary lesion located at the bladder dome, with histopathological evaluation confirming LELC. He received neoadjuvant chemotherapy; however, follow-up cystoscopy revealed recurrence. A repeat endoscopic resection confirmed persistent disease, and the patient subsequently underwent partial cystectomy. Two follow-up cystoscopies showed no evidence of recurrence. Bladder LELC may present in pure, predominant, or focal forms, with prognosis influenced by the proportion of lymphoepithelial components. Immunohistochemistry is essential for diagnosis. Although Epstein-Barr virus has been associated with LELC in other sites, it has not been implicated in the bladder. Multimodal treatment, typically involving surgery and cisplatin-based chemotherapy, is commonly employed. In this case, partial cystectomy led to favorable short-term outcomes. Further research is needed to establish standardized treatment protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.